The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

The excitement of two COVID-19 vaccines with more than 90 percent efficacy is undeniable. In November, both Pfizer and Moderna announced its scientists had developed vaccines with efficacy at or near ...

SAN FRANCISCO -- Another COVID-19 vaccine -- AstraZeneca -- is poised to arrive in the U.S., bringing a fourth option for Americans. Each vaccine is administered slightly differently, some can result ...

LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...

The United States is poised to get a third coronavirus vaccine -- this one made by Johnson & Johnson. The US Food and Drug Administration has given the vaccine emergency use authorization, the Centers ...

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, giving the world another important tool to halt the COVID-19 pandemic.